Abstract: A fluidic artificial muscle actuator may include at least one inflatable bladder defining a first inflatable segment coupled to a first member and to a second member arranged at opposite ends of the first inflatable segment, and a second inflatable segment coupled to a third member and to a fourth member arranged at opposite ends of the second inflatable segment, and an effector coupled to the first inflatable segment and to the second inflatable segment for providing an actuator output. The first inflatable segment is configured to contract in a longitudinal direction with increase in fluid pressure in the first inflatable segment and the second inflatable segment is configured to extend in the longitudinal direction with increase in fluid pressure in the second inflatable segment.

Abstract: A fluidic artificial muscle actuator may include at least one inflatable bladder defining a first inflatable segment coupled to a first member and to a second member arranged at opposite ends of the first inflatable segment, and a second inflatable segment coupled to a third member and to a fourth member arranged at opposite ends of the second inflatable segment, and an effector coupled to the first inflatable segment and to the second inflatable segment for providing an actuator output. The first inflatable segment is configured to contract in a longitudinal direction with increase in fluid pressure in the first inflatable segment and the second inflatable segment is configured to extend in the longitudinal direction with increase in fluid pressure in the second inflatable segment.

Abstract: An electrosurgical wand is disclosed for treating a plurality of tissues at a variety of tissue locations. The electrosurgical wand includes a handle on a proximal end and an elongate shaft with a combination active electrode at the distal end. The combination active electrode includes with a blade and screen portion; the blade portion extending along and laterally from the wand longitudinal axis, forming a dissecting tip. The screen portion extends from the blade portion at an obtuse angle and has at least one aspiration aperture through it. The wand also includes a second and third electrode, proximally spaced from the combination active electrode. The second electrode spans a portion of an outside surface of the wand adjacent the blade portion, while the third electrode spans a portion of the outside surface of the wand opposite the second electrode.

Abstract: An electrosurgical wand is disclosed for treating a plurality of tissues at a variety of tissue locations. The electrosurgical wand includes a handle on a proximal end and an elongate shaft with a combination active electrode at the distal end. The combination active electrode includes with a blade and screen portion; the blade portion extending along and laterally from the wand longitudinal axis, forming a dissecting tip. The screen portion extends from the blade portion at an obtuse angle and has at least one aspiration aperture through it. The wand also includes a second and third electrode, proximally spaced from the combination active electrode. The second electrode spans a portion of an outside surface of the wand adjacent the blade portion, while the third electrode spans a portion of the outside surface of the wand opposite the second electrode.

Abstract: A hydrophobic topical skin composition is disclosed. The composition includes greater than 50% w/w of the composition of a continuous hydrophobic carrier, 5-24% w/w of one or more volatile silicone fluids, and 0.1 to 5% w/w of the composition of a plurality of taxane nanoparticles, wherein the mean particle size (number) of the taxane nanoparticles is from 0.1 microns to 1.5 microns, and wherein the taxane nanoparticles are crystalline nanoparticles or a combination of amorphous and crystalline nanoparticles.

Abstract: A hydrophobic topical skin composition is disclosed. The composition includes greater than 50% w/w of the composition of a continuous hydrophobic carrier, 5-24% w/w of one or more volatile silicone fluids, and 0.1 to 5% w/w of the composition of a plurality of taxane nanoparticles, wherein the mean particle size (number) of the taxane nanoparticles is from 0.1 microns to 1.5 microns, and wherein the taxane nanoparticles are crystalline nanoparticles or a combination of amorphous and crystalline nanoparticles.

Abstract: An electrosurgical wand is disclosed for treating a plurality of tissues at a variety of tissue locations. The electrosurgical wand includes a handle on a proximal end and an elongate shaft with a combination active electrode at the distal end. The combination active electrode includes with a blade and screen portion; the blade portion extending along and laterally from the wand longitudinal axis, forming a dissecting tip. The screen portion extends from the blade portion at an obtuse angle and has at least one aspiration aperture through it. The wand also includes a second and third electrode, proximally spaced from the combination active electrode. The second electrode spans a portion of an outside surface of the wand adjacent the blade portion, while the third electrode spans a portion of the outside surface of the wand opposite the second electrode.

Abstract: An electrosurgical wand is disclosed for treating a plurality of tissues at a variety of tissue locations. The electrosurgical wand includes a handle on a proximal end and an elongate shaft with a combination active electrode at the distal end. The combination active electrode includes with a blade and screen portion; the blade portion extending along and laterally from the wand longitudinal axis, forming a dissecting tip. The screen portion extends from the blade portion at an obtuse angle and has at least one aspiration aperture through it. The wand also includes a second and third electrode, proximally spaced from the combination active electrode. The second electrode spans a portion of an outside surface of the wand adjacent the blade portion, while the third electrode spans a portion of the outside surface of the wand opposite the second electrode.

Abstract: An electrosurgical wand is disclosed for providing a range of tissue treatment modes and for use in a variety of orientations. The electrosurgical wand includes a handle on a proximal end, an elongate shaft and at least three distinct electrodes disposed at a distal end of the wand. The three electrodes include a blade electrode having a length measured parallel to a longitudinal axis of wand, the length running parallel to the wand longitudinal axis for a portion of the length. The blade electrode has a distal portion that curves toward the longitudinal axis at the distal end of the wand. The three electrodes also include a second electrode disposed on a second side of the wand from the blade electrode; and a third electrode disposed between the blade electrode and the second electrode. All the electrodes have a different shape and surface area.

Abstract: A hydrophobic topical skin composition is disclosed. The composition includes greater than 50% w/w of the composition of a continuous hydrophobic carrier, 5-24% w/w of one or more volatile silicone fluids, and 0.1 to 5% w/w of the composition of a plurality of taxane nanoparticles, wherein the mean particle size (number) of the taxane nanoparticles is from 0.1 microns to 1.5 microns, and wherein the taxane nanoparticles are crystalline nanoparticles or a combination of amorphous and crystalline nanoparticles.

Abstract: Disclosed are compositions and methods useful for enhancing the skin penetration of drug nanoparticles. The compositions can be hydrophobic and include a hydrophobic carrier, a volatile silicone fluid, and drug nanoparticles. Also disclosed are methods for inhibiting crystal growth of drug nanoparticles in an aqueous carrier or a hydrophobic carrier. Further, methods to topically treat psoriasis using compositions containing nanoparticles of paclitaxel or other taxanes are disclosed.

Abstract: An electrosurgical wand is disclosed for treating a plurality of tissues at a variety of tissue locations. The electrosurgical wand includes a handle on a proximal end and an elongate shaft with a combination active electrode at the distal end. The combination active electrode includes with a blade and screen portion; the blade portion extending along and laterally from the wand longitudinal axis, forming a dissecting tip. The screen portion extends from the blade portion at an obtuse angle and has at least one aspiration aperture through it. The wand also includes a second and third electrode, proximally spaced from the combination active electrode. The second electrode spans a portion of an outside surface of the wand adjacent the blade portion, while the third electrode spans a portion of the outside surface of the wand opposite the second electrode.

Abstract: An electrosurgical wand is disclosed for providing a range of tissue treatment modes and for use in a variety of orientations. The electrosurgical wand includes a handle on a proximal end, an elongate shaft and at least three distinct electrodes disposed at a distal end of the wand. The three electrodes include a blade electrode having a length measured parallel to a longitudinal axis of wand, the length running parallel to the wand longitudinal axis for a portion of the length. The blade electrode has a distal portion that curves toward the longitudinal axis at the distal end of the wand. The three electrodes also include a second electrode disposed on a second side of the wand from the blade electrode; and a third electrode disposed between the blade electrode and the second electrode. All the electrodes have a different shape and surface area.

Abstract: Disclosed are compositions and methods useful for enhancing the skin penetration of drug nanoparticles. The compositions can be hydrophobic and include a hydrophobic carrier, a volatile silicone fluid, and drug nanoparticles. Also disclosed are methods for inhibiting crystal growth of drug nanoparticles in an aqueous carrier or a hydrophobic carrier. Further, methods to topically treat psoriasis using compositions containing nanoparticles of paclitaxel or other taxanes are disclosed.

Abstract: The invention relates to a medicament containing a compound of general formula (I), where R1=independently, a straight or branched, saturated, singly- or multiply-unsaturated, optionally substituted C11-C21 alkyl, alkylene or alkinyl group, preferably a C11-C15 alkyl, alkylene or alkinyl group, particularly a C11-C13 alkyl, alkylene or alkinyl group, most preferably a C13 alkyl group, R2=independently, a straight or branched C1-C8 alkyl, alkylene or alkinyl group, preferably a C1-C6 alkyl, alkylene or alkinyl group, in particular a C2-C4 alkyl, alkylene or alkinyl group, most preferably a C3 alkyl group, a —[CH2—(CH2)m—O]nH group with n=1 to 10, preferably n=1 to 5, to m=1 to 5, preferably m=1 to 3, a —CH2—[CH—(OH)]p [CH2—R3]-group, where R3=independently H or OH, p=1 to 7, preferably p=1 to 4, a pentose group or a hexose group, as therapeutically active agent, alone or in combination with one or several further pharmaceutical agents as a combination preparation for the treatment of viral skin diseases and/or

Abstract: Disclosed are compositions and methods useful for enhancing the skin penetration of drug nanoparticles. The compositions can be hydrophobic and include a hydrophobic carrier, a volatile silicone fluid, and drug nanoparticles. Also disclosed are methods for inhibiting crystal growth of drug nanoparticles in an aqueous carrier or a hydrophobic carrier. Further, methods to topically treat psoriasis using compositions containing nanoparticles of paclitaxel or other taxanes are disclosed.

Abstract: The invention relates to a medicament containing a compound of general formula (I), where R1=independently, a straight or branched, saturated, singly- or multiply-unsaturated, optionally substituted C11-C21 alkyl, alkylene or alkinyl group, preferably a C11-C15 alkyl, alkylene or alkinyl group, particularly a C11-C13 alkyl, alkylene or alkinyl group, most preferably a C13 alkyl group, R2=independently, a straight or branched C1-C8 alkyl, alkylene or alkinyl group, preferably a C1-C6 alkyl, alkylene or alkinyl group, in particular a C2-C4 alkyl, alkylene or alkinyl group, most preferably a C3 alkyl group, a —[CH2—(CH2)m-O]nH group with n=1 to 10, preferably n=1 to 5, to m=1 to 5, preferably m=1 to 3, a —CH2—[CH—(OH)]p[CH2—R3]— group, where R3=independently H or OH, p=1 to 7, preferably p=1 to 4, a pentose group or a hexose group, as therapeutically active agent, alone or in combination with one or several further pharmaceutical agents as a combination preparation for the treatment of viral skin diseases and/or

Abstract: The present disclosure generally relates to pharmaceutical corticosteroid compositions, and methods of making the same.

Abstract: The invention relates to a medicament containing a compound of general formula (I), where R1=independently, a straight or branched, saturated, singly- or multiply-unsaturated, optionally substituted C11-C21 alkyl, alkylene or alkinyl group, preferably a C11-C15 alkyl, alkylene or alkinyl group, particularly a C11-C13 alkyl, alkylene or alkinyl group, most preferably a C13 alkyl group, R2=independently, a straight or branched C1-C8 alkyl, alkylene or alkinyl group, preferably a C1-C6 alkyl, alkylene or alkinyl group, in particular a C2-C4 alkyl, alkylene or alkinyl group, most preferably a C3 alkyl group, a —[CH2—(CH2)m-O]nH group with n=1 to 10, preferably n=1 to 5, to m=1 to 5, preferably m=1 to 3, a —CH2—[CH—(OH)]p [CH2—R3]— group, where R3=independently H or OH, p=1 to 7, preferably p=1 to 4, a pentose group or a hexose group, as therapeutically active agent, alone or in combination with one or several further pharmaceutical agents as a combination preparation for the treatment of viral skin diseases and/o

Abstract: Disclosed are compositions and methods useful for enhancing the skin penetration of drug nanoparticles. The compositions can be hydrophobic and include a hydrophobic carrier, a volatile silicone fluid, and drug nanoparticles. Also disclosed are methods for inhibiting crystal growth of drug nanoparticles in an aqueous carrier or a hydrophobic carrier. Further, methods to topically treat psoriasis using compositions containing nanoparticles of paclitaxel or other taxanes are disclosed.